HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Oncternal Therapeutics (NASDAQ:ONCT) but lowers the price target from $30 to $28.

April 15, 2024 | 10:10 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oncternal Therapeutics' Buy rating is maintained by HC Wainwright & Co., but the price target is reduced from $30 to $28.
The maintenance of a Buy rating suggests a positive outlook on Oncternal Therapeutics by HC Wainwright & Co., indicating confidence in the company's fundamentals or growth prospects. However, the reduction in the price target could reflect a reassessment of the company's future earnings potential, market conditions, or both. This mixed signal might lead to short-term uncertainty among investors, potentially causing minor fluctuations in the stock price. The overall impact is considered neutral since the positive endorsement of the company's prospects is somewhat counterbalanced by the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100